P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)
Conditions
Prostatic Neoplasms, Castration-Resistant · Neoplasms by Histologic Type · Neoplasms, Prostate · Prostate Cancer · Metastatic Castration-resistant Prostate Cancer · Neoplasms · Prostatic Neoplasms · Genital Neoplasms, Male · Urogenital Neoplasms · Neoplasms by Site · Prostatic Disease · Salivary Gland Cancer · Salivary Gland Tumor · Adenoid Cystic Carcinoma · Salivary Duct Carcinoma · Mucoepidermoid Carcinoma · Acinic Cell Tumor
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
City of Hope Comprehensive Cancer Center, Duarte, California, United States
University of California San Diego, San Diego, California, United States
University of California San Francisco, San Francisco, California, United States
Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States
Tulane University Hospital and Clinic, New Orleans, Louisiana, United States
University of Maryland, Baltimore, Baltimore, Maryland, United States
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Massachusetts General Hospital, Boston, Massachusetts, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Tennessee Oncology, Nashville, Tennessee, United States
Study leads
Rajesh Belani, M.D.
Study Director
Sponsor Executive Medical Director